IMPACT BIOMEDICAL INC.

Impact Biomedical Inc. ( IBO . Impact , Impact BioMedical , we , us , our or the Company ) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships, and currently trades on the NYSE American under ticker symbol IBO. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBO technologies in exchange for milestone, and royalty payments. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. ( Global BioLife ), which was incorporated on April 14, 2017, (ii) Impact BioLife Science, Inc. ( Impact BioLife ), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. ( Global BioMedical ), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc.